While these tumors differ in their methylation pattern from their SMARCB1 deleted counterparts, heterozygous aberrations in SMARCA4 so far have not been implicated in the biology of rhabdoid tumors. This evidence concerns the gene SMARCA4 and rhabdoid tumor.